The effect of immobilization on myocellular characteristics in healthy, young males

Completed

• Conditions: Sarcopenia; 10028302

• Registration Number: NL-OMON36909
• Lead Sponsor: niversiteit Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 15

Inclusion Criteria

Male
Age between 18 and 35 years old
BMI <= 30

Exclusion Criteria

Use of medication that may affect haemostasis
Subjects with (recent) musculoskeletal/orthopaedic disorders known to affect the outcome of the study or that compromise their ability to walk with crutches.
Subjects with metal implants in their lower limbs
Subjects with known current cardiovascular disease
Subjects with cardiovascular disease in their history
Subjects with known current haemostatic disorders
Subjects with haemostatic disorders in their history;Previously experienced side effects of heparine-like coagulant medication
Blood loss from tractus digestivus (ulcus pepticum, tumor, hiatus hernia or diverticulosis)
Surgery of cerebrum, eyes or spinal cord during fraxiparine application period
Lumbar puncture during fraxiparine application period
Anaesthesia (regional or spinal) during fraxiparine application period
Renal dysfunction

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Muscle charateristics and satellite cell content, at 0, 2 and 8 weeks after the<br /><br>start of the intervention.<br /><br>In addition, muscle protein synthesis rate will be determined at 0 en 2 wks.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Maximal strength<br /><br>Cross-sectional area of the upper leg</p><br>